Sugi Predict

Sugi Predict / Targets / PTPN5

PTPN5

Tyrosine-protein phosphatase non-receptor type 5 · P54829 · PTPN5 on Sugi Atlas →

48,009 patent compounds predicted against PTPN5, 29,956 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL325885 SCHEMBL325885 0.56 12/20
SCHEMBL97543 SCHEMBL97543 0.56 3/20
SCHEMBL148417 SCHEMBL148417 0.55 3/20
SCHEMBL95649 SCHEMBL95649 0.55 3/20
SCHEMBL95092 SCHEMBL95092 0.53 3/20
SCHEMBL95797 SCHEMBL95797 0.53 3/20
SCHEMBL95378 SCHEMBL95378 0.52 3/20
SCHEMBL96292 SCHEMBL96292 0.52 3/20
SCHEMBL97052 SCHEMBL97052 0.52 3/20
SCHEMBL60703 SCHEMBL60703 0.46 3/20
SCHEMBL447980 SCHEMBL447980 0.45 3/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL444567) 0.42 3/20
SCHEMBL300805 SCHEMBL300805 0.42 3/20
SCHEMBL398059 SCHEMBL398059 0.42 3/20
SCHEMBL382817 SCHEMBL382817 0.34 3/20
SCHEMBL154124 SCHEMBL154124 1.00 2/20
SCHEMBL156692 SCHEMBL156692 0.76 2/20
Salicylaldehyde Benzoyl Hydrazone Salicylaldehyde Benzoyl Hydrazone (SCHEMBL414977) 0.70 2/20
Salicylaldehyde Benzoyl Hydrazone Salicylaldehyde Benzoyl Hydrazone (SCHEMBL414978) 0.70 2/20
SCHEMBL343391 SCHEMBL343391 0.66 2/20

Clinical trials — most relevant to PTPN5 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Pegylated-Interferon and Ribavirin Plus Metformin in the Treatment of Chronic HCV Infection and Insulin Resistance PHASE4UNKNOWN
A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia PHASE3RECRUITING
Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study) PHASE1/PHASE2WITHDRAWN
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma PHASE2RECRUITING
Pembrolizumab (MK-3475) in MM Patients With Residual Disease PHASE2COMPLETED
Study in Adult Ph-positive ALL PHASE2UNKNOWN
An Exploratory Study on the Use of Ipalotinib (Tislelizumab) Combined With Sunitinib and Olaparib for Neoadjuvant Therapy in HRD-positive Advanced Ovarian Cancer PHASE2RECRUITING
Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease PHASE2COMPLETED
Cyclosporine For The Treatment Of COVID-19(+) PHASE2COMPLETED
SUTENT (SUNITINIB, SU11248)in Patients With Recurrent or Progressive Glioblastoma Multiforme PHASE2UNKNOWN
Phase I Study of SC-43 Oral Solution in Subjects With Refractory Solid Tumors PHASE1WITHDRAWN
A Study of HMPL-415S1 in Patients With Advanced Malignant Solid Tumors PHASE1RECRUITING
Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency PHASE1RECRUITING
Lymphoid Tyrosine Phosphatase Gene Polymorphisms in Inflammatory Bowel Disease nanUNKNOWN
Immunophenotypic Evaluation of CD305 and CD85d in B-Cell Lymphoid Neoplasms nanNOT_YET_RECRUITING
Role of NFKBIA and PTPN22 Genes Polymorphism in Acute Rejection Susceptibility After Living Donor Liver Transplantation in Egyptian Patients. nanCOMPLETED
Resistance to Immunotherapy in Gastric Cancer nanUNKNOWN
Cytotoxic T Lymphocyte-Associated Antigen-4 (CTLA-4) Gene Single-nucleotide Polymorphism in Primary Immune Thrombocytopenic Purpura in Children nanNOT_YET_RECRUITING
What is the Impact of TKI on Thyroid Function in CML Patients? nanNOT_YET_RECRUITING
rT3 and Inflammation in Hashimoto's Thyroiditis nanCOMPLETED
Is T-lymphocyte Calcineurin Phosphatase Up-regulated by Treatment With Tacrolimus? nanCOMPLETED
Monitoring of Breathing Effort Through Pressure Time Product Measurement Using Airway Occlusion Pressure nanUNKNOWN
Modulatory Effect of Prodigiosin or Pioglitazone on TIME and the Crosstalk to Immune-Checkpoint Protein(s) nanNOT_YET_RECRUITING
Quantification of GADD34 Expression in RA nanCOMPLETED
Identification of the Genetic Variants Responsible for Primary Biliary Cirrhosis (PBC) nanUNKNOWN
Clinical Study on the Application of PET Probes Targeting DDR2 in the Diagnosis of Interstitial Lung Disease With Cognitive Impairment nanNOT_YET_RECRUITING
NGS in Gallbladder Cancer and Response to Treatment nanRECRUITING
Ibrutinib Adapted to Response in Patients With CLL nanUNKNOWN
Expression of CD19 Complex in Lymphoproliferative Disorders nanUNKNOWN
Clinical Research for Azacitidine Combined With Low-dose Dasatinib in Maintenance Therapy of Acute Myeloid Leukemia nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a PTPN5 binder may also engage these)

ProteinNameSimilarity
P54830 — 1.000 P54830 →
Q8K330 — 0.991 Q8K330 →
PTPRR Receptor-type tyrosine-protein phosphatase R 0.989 landscape →
D3YWQ0 — 0.988 D3YWQ0 →
Q8BHW9 — 0.988 Q8BHW9 →
P0C6P5 — 0.987 P0C6P5 →
Q62132 — 0.987 Q62132 →
Q9R117 — 0.987 Q9R117 →
Q8CFK6 — 0.986 Q8CFK6 →
Q6PFD6 — 0.986 Q6PFD6 →
Q924U5 — 0.986 Q924U5 →
Q60700 — 0.986 Q60700 →
Q8TDY4 — 0.986 Q8TDY4 →
USP19 Ubiquitin carboxyl-terminal hydrolase 19 0.986 landscape →
Q9BQI7 — 0.986 Q9BQI7 →
PTPN7 Tyrosine-protein phosphatase non-receptor type 7 0.986 landscape →
Q80TF6 — 0.986 Q80TF6 →
F1MAB7 — 0.986 F1MAB7 →
Q63553 — 0.986 Q63553 →
Q28969 — 0.985 Q28969 →
Q4VSN4 — 0.985 Q4VSN4 →
Q28314 — 0.985 Q28314 →
Q6P1I6 — 0.985 Q6P1I6 →
O89084 — 0.985 O89084 →
Q6IVY4 — 0.985 Q6IVY4 →
O35071 — 0.985 O35071 →
Q5BIW4 — 0.985 Q5BIW4 →
Q96PD2 — 0.985 Q96PD2 →
TYK2 Non-receptor tyrosine-protein kinase TYK2 0.985 landscape →
D3ZML2 — 0.985 D3ZML2 →